NEVERMINED-AG
12.7.2022 15:02:09 CEST | Business Wire | Press release
Nevermined AG , a Web3 company that provides tools to read, write and own your digital assets, announced their initial investment round of €3 million, co-led by Signature Ventures and Polymorphic Capital. The Nevermined platform consists of modular solutions that easily allow users the ability to create and monetize digital assets and participate in the read-write-own vision of Web3.
The platform offers the foundations for building digital ecosystems with components like Tokenization Engine, Marketplace Creator, Royalties Engine, Decentralized Access Control, DAO Framework and DISC, or Data In-Situ Computation, for Remote Computation.
Nevermined CEO Don Gossen shares, “The best internet is the one that everyone can access and own. And this is what Nevermined allows people to do. When it comes to Data mixed with Web3 our pedigree speaks for itself – our team has been working with cutting-edge tech for over 20 years, first in Big Data, and now in Web3. With these building blocks, we can help you realize your vision. I’d argue we’re the best team in the world that does what we do.”
According to a new report by Grand View Research , the global blockchain technology market size is expected to reach $1,431 billion by 2030. With this market opportunity and its solid, proven technology, Nevermined will leverage this capital raise to:
Be more complete and scalable by advancing its product roadmap: Nevermined will enhance its digital asset development platform that makes Web3 accessible by streamlining the creation, monetization and management of decentralized digital assets. Some key projects include:
- Enterprise: A global energy company used the platform to create a peer-to-peer carbon certificate trading marketplace.
- Creative: Autonomies is using Nevermined to build a music NFT platform and DAO, allowing for fairer value distribution between musicians, labels and collectors.
- Science: In a world first, VitaDAO used Nevermined to tokenize the IP of scientific research, conducted by the Scheibye-Knudsen Lab in Copenhagen.
Be more accessible by accelerating global footprint: To foster company growth and better customer experience, Nevermined will be strengthening its presence in key areas including product, engineering, marketing and community.
Be easier to use by expanding the breadth and depth of the partner ecosystem: Nevermined will establish both technical and creative partnerships that will bolster its mission. Along with deepening partnerships with initiatives such as Autonomies , a music NFT platform allowing artists to become stakeholders.
“We only invest in outstanding teams that build the backbone of the decentralized future,'' said Managing Director Juliane Hahn, Signature. “We see many startups that try to combine Data with Blockchains. Nevermined is the first company that understands the complexities and provides actual solutions at the intersection of Data and Web3. In the future every data-driven company will require the ability to turn their data silos into data ecosystems. Nevermined delivers the full product stack to do just that.”
“We’ve been very impressed with the Nevermined team,” said Vitaly Spassky, founder of Polymorphic Capital. “They have the vision, as well as the tech talent and pedigree to execute. To us digital assets are a crucial building block for the decentralized web. And the Nevermined platform makes it super easy for teams and projects to integrate Web3 tech. We’re very excited to see what people will build with Nevermined.”
Nevermined began as an incubation project within Keyko AG to solve issues around data sharing using tokenization and smart contract gateways. From there it evolved from a data-centric solution to a decentralized digital assets solution with much broader applicability.
About Nevermined
Nevermined is a Web3 company that provides tools to read, write and own your digital assets, founded by CEO Don Gossen, CTO Aitor Argomaniz and CIO Dimitri De Jonghe. They met while creating Ocean Protocol, the world’s first decentralized data marketplace. In 2019, they founded Keyko over a shared belief in the power of digital ecosystems. They helped a variety of organizations develop Web3 ecosystems, worth a combined value of $3 billion. In 2022, they decided to spin out Nevermined as a standalone technology platform.
More info on https://nevermined.io/
About Signature Ventures
Signature Ventures is an early-stage Venture Capital fund investing in Blockchain, Distributed Ledger Technology and Web3 technology. Based in Germany, the fund invests in Pre-Seed to Series A, globally with a focus on Europe. Signature Ventures is managed by Juliane Hahn, Founding Partner, and Dr. Georg Stricker, Tech Partner. They combine an extensive track record of VC investments with deep Blockchain expertise.
About Polymorphic Capital
Polymorphic Capital is a venture capital firm that invests globally in teams creating the future of the internet with decentralized protocols and digital assets. They specialize in infrastructure, finance and gaming.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005503/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom